Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 35 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med 2019;179:8 de julio. [Ref.ID 103170]
2. Cita con resumen
Anónimo. Baricitinib et polyarthrite rhumatoïde. Prescrire 2018;38:171-2. [Ref.ID 102586]
3. Cita con resumen
Smolen JS, Burmester G-R, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74. [Ref.ID 101029]
4. Cita con resumen
Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendiing D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza J-M, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers Y-M, Gayraud M, Bolla G, Glaudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc J-C, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P. Non-TNF-tarteged biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 2016;316:1172-80. [Ref.ID 100753]
5. Cita con resumen
French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-a agents. Drug Saf 2016;39:199-208. [Ref.ID 100140]
6. Cita con resumen
Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum 2016;68:56-66. [Ref.ID 99975]
7. Cita con resumen
Sansone AC, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, Marino A, Fornai M, Antonioli L, Corona T, Garibaldi D, Blandizzi C. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory disease: a systematic review and meta-analysis. Drug Saf 2015;38:869-88. [Ref.ID 99614]
8. Cita con resumen
Anónimo. Drugs for rheumatoid arthritis. Med Lett Drugs Ther 2014;56:127-32. [Ref.ID 98445]
9. Cita con resumen
Anónimo. Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:59-66. [Ref.ID 98172]
10. Cita con resumen
Anónimo. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. Med Lett Drugs Ther 2014;56:10-2. [Ref.ID 97221]
11. Cita con resumen
Anónimo. TNF inhibitors for Crohn's disease: when, which, and for how long. Med Lett Drugs Ther 2013;55:102-3. [Ref.ID 96731]
12. Cita con resumen
Simon PC, Vallano A. Fármacos que inhiben el factor de necrosis tumoral alfa y embarazo. Med Clin (Barc) 2013;141:257-9. [Ref.ID 96078]
13.
Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [Ref.ID 95460]
17. Cita con resumen
Miselli M. Golimumab. Informazioni sui Farmaci 2011;35:46-9. [Ref.ID 91410]
18.
Miselli M. Certolizumab pegol. Informazioni sui Farmaci 2011;35:3-4. [Ref.ID 90528]
19. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
20. Cita con resumen
Klarenbeek NB, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Recent advances in the management of rheumatoid arthritis. BMJ 2011;342:39-44. [Ref.ID 90005]
Seleccionar todas
 
 1 a 20 de 35 siguiente >>